Description:
ADRENOLEUKODYSTROPHY; ALD
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases |
| Class |
Disorders of Steroid Metabolism |
|
Cell Type
|
Fibroblast
|
|
Tissue Type
|
Skin
|
|
Transformant
|
Untransformed
|
|
Race
|
White
|
|
Family Member
|
1
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Clinical summary/Case history
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
3.86 |
| Passage Frozen |
8 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
| |
| Remarks |
Clinically affected; adrenomyeloneuropathy; adrenal insufficiency; hyperreflexia; stiff limbs; hand tremors; ataxic and spastic gait; spastic paraparesis; occasional nausea & vomiting; increased frequency of urination; normal thyroid function tests; elevated levels of C26 fatty acids in plasma & fibro (quantitated by capillary gas liquid chromatography); treatments include: cortisone and hydrocortisone; negative family history. |
| Lee DK, Long NP, Jung J, Kim TJ, Na E, Kang YP, Kwon SW, Jang J, Integrative lipidomic and transcriptomic analysis of X-linked adrenoleukodystrophy reveals distinct lipidome signatures between adrenomyeloneuropathy and childhood cerebral adrenoleukodystrophy Biochemical and biophysical research communications: 2018 |
| PubMed ID: 30509496 |
| |
| Pahan K, Khan M, Singh I, Therapy for X-adrenoleukodystrophy: normalization of very long chain fatty acids and inhibition of induction of cytokines by cAMP. J Lipid Res39(5):1091-100 1998 |
| PubMed ID: 9610777 |
| Gene Cards |
ALD |
| NCBI GTR |
300100 ADRENOLEUKODYSTROPHY; ALD |
| OMIM |
300100 ADRENOLEUKODYSTROPHY; ALD |
| Omim Description |
ADDISON DISEASE AND CEREBRAL SCLEROSIS |
| |
ADRENOLEUKODYSTROPHY; ALD |
| |
ADRENOMYELONEUROPATHY; AMN |
| |
BRONZE SCHILDER'S DISEASE |
| |
MELANODERMIC LEUKODYSTROPHYADRENOLEUKODYSTROPHY PROTEIN, INCLUDED; ALDP, INCLUDED |
| |
SIEMERLING-CREUTZFELDT DISEASE |
| Passage Frozen |
8 |
| Split Ratio |
1:2 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Supplement |
- |
|